Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
Ghana's pharmaceutical market is a growing industry that has been experiencing significant development in recent years.
Customer preferences: Ghanaians are becoming increasingly health-conscious, which is driving the demand for pharmaceutical products in the country. The population is also growing, leading to an increase in demand for healthcare services and products. Additionally, the government has been investing heavily in the healthcare sector, which has resulted in increased access to healthcare services and products.
Trends in the market: One of the major trends in the Ghanaian pharmaceutical market is the growing demand for generic drugs. This is due to the fact that they are more affordable than branded drugs and are widely available. Another trend is the increasing use of technology in the healthcare sector, which has led to the development of telemedicine and e-pharmacy services. The COVID-19 pandemic has also had a significant impact on the market, with increased demand for pharmaceutical products such as hand sanitizers and personal protective equipment.
Local special circumstances: Ghana has a relatively stable political environment, which has been conducive to the growth of the pharmaceutical industry. The country is also strategically located in West Africa, making it an attractive destination for pharmaceutical companies looking to expand their operations in the region. Additionally, the government has implemented policies to support the growth of the industry, such as the reduction of import duties on pharmaceutical products.
Underlying macroeconomic factors: The Ghanaian economy has been growing steadily in recent years, with a GDP growth rate of 6.5% in 2019. This has led to increased disposable income, which has translated into increased demand for pharmaceutical products. The government's investment in the healthcare sector has also contributed to the growth of the industry. However, there are still challenges that need to be addressed, such as the high cost of healthcare services and products, which limits access for some segments of the population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)